Teva Canada Announces New Autoinjector for AJOVY for the Preventive Treatment of Migraine in Adults
Teva Canada, a subsidiary of Teva Pharmaceutical Industries Ltd., today announced the launch and availability of a new autoinjector for AJOVY (fremanezumab). AJOVY is a subcutaneous injection for the preventive treatment of migraine in adults who have at least four migraine days per month. When launched in 2020, AJOVY was available in a prefilled syringe only. The product is now available in two latex-free1 formats: a new autoinjector and a prefilled syringe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210408005437/en/
Teva Canada announces new autoinjector for AJOVY (fremanezumab) for the preventive treatment of migraine in adults. (Photo: Business Wire)
AJOVY is the first and only product in its class that is available in multiple formats, providing two unique injection devices and two optional dosing regimens. It is also the first and only subcutaneous anti-CGRP (calcitonin gene-related peptide) drug approved in Canada, the European Union, and the United States that offers quarterly (225 mg) or monthly (675 mg) dosing regimens using either the autoinjector or prefilled syringe for the preventive treatment of migraine.1,2,3 The new AJOVY autoinjector also has several features that make it easy-to-use4 including a button-free, push-down mechanism; audible cues that signal progress of administration; and, a window that displays when the dose has been delivered. Additionally, the autoinjector is for one-time use only and locks after use.
“Migraine patients are highly individual—not all want the same device. At Teva Canada, we believe in the power of choice and we believe that options are important for patients and prescribers,” says Christine Poulin, Teva Canada’s General Manager. “From the beginning, AJOVY has offered flexible dosing options. With the launch of this new device, AJOVY now also offers different injection options. I see AJOVY as a complete package of care, with injection training and other support delivered through our AJOVY Teva Support Solutions (AJOVY TSS) Patient Support Program.”
Lesen Sie auch
“For many Canadians, migraine is a debilitating regular occurrence that greatly impacts a patient’s ability to carry out day-to-day functions. Having another option in the AJOVY family of treatments allows patients to manage their condition to suit their lifestyle,” said Dr. Elizabeth Leroux, President of the Canadian Headache Society and Founder of the websites Migraine Quebec and Migraine Canada. “Recent changes in the field of migraine treatment have opened a lot of doors; this new injection option with flexible dosing opens yet another one for patients and health care providers who manage migraine.”